Healthcare Databases for Drug Safety Research: Data Validity Assessment Remains Crucial
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Healthcare Databases for Drug Safety Research: Data Validity Assessment Remains Crucial
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-04-30
DOI
10.1007/s40264-018-0673-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Electronic Health Data for Postmarket Surveillance: A Vision Not Realized
- (2015) Thomas J. Moore et al. DRUG SAFETY
- Restrictive Reimbursement Policies: Bias Implications for Claims-Based Drug Safety Studies
- (2014) Joshua J. Gagne DRUG SAFETY
- Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis
- (2013) Kristian B Filion et al. GUT
- Mini-Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research
- (2012) Ryan M. Carnahan PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database
- (2010) Najat Ziyadeh et al. CLINICAL THERAPEUTICS
- Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
- (2010) David J. Graham et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Database Evaluation of the Effects of Long-Term Rosiglitazone Treatment on Cardiovascular Outcomes in Patients With Type 2 Diabetes
- (2010) Ronen Loebstein et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients
- (2009) Alain Vanasse et al. Diabetes & Vascular Disease Research
- Rapid Identification of Myocardial Infarction Risk Associated With Diabetes Medications Using Electronic Medical Records
- (2009) J. S. Brownstein et al. DIABETES CARE
- Thiazolidinediones and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus
- (2009) Fei-Yuan Hsiao et al. DRUG SAFETY
- Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis
- (2009) Zeina A. Habib et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Association Between Extent of Thiazolidinedione Exposure and Risk of Acute Myocardial Infarction
- (2009) David D Dore et al. PHARMACOTHERAPY
- Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
- (2009) Colin R. Dormuth et al. PLoS One
- Comparison of Cardiovascular Outcomes in Elderly Patients With Diabetes Who Initiated Rosiglitazone vs Pioglitazone Therapy
- (2008) Wolfgang C. Winkelmayer et al. ARCHIVES OF INTERNAL MEDICINE
- Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007
- (2008) Alexander M. Walker et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients
- (2008) Carol E. Koro et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Association between serious ischemic cardiac outcomes and medications used to treat diabetes
- (2008) David J. Margolis et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications
- (2008) Karen M. Stockl et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Manitoba and Saskatchewan administrative health care utilization databases are used differently to answer epidemiologic research questions
- (2007) Andrea C. Tricco et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started